Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Press Release
Article
Camber Pharmaceuticals Announces Addition of Nimodipine Oral Solution
Key Takeaways
- Nimodipine Oral Solution targets ischemic deficits in adults with SAH from ruptured intracranial berry aneurysms.
- The solution is effective irrespective of the patient's neurological status post-ictus.
Camber Pharmaceuticals is excited to announce the addition of Nimodipine Oral Solution.
Nimodipine Oral Solution is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition.
Nimodipine Oral Solution 60 mg/20 mL (3 mg/mL) is available and packaged in a 16-ounce bottle.
To find out more information on Nimodipine Oral Solution, please visit: www.camberpharma.com/nimodipine
Related Videos
Related Content
